Feature Image

Study Finds CBD-Based Topical Improves Skin Appearance

A facial serum containing cannabidiol was shown to improve the facial skin appearance of every participant in a recent clinical trial.

clinical trial testing the effects of a cannabidiol (CBD) facial serum found a 100 percent overall improvement in skin appearance following two weeks of treatment.

CBD is a natural, non-psychoactive compound found throughout the seeds, stalks, and flowers of cannabis plants. It’s found in higher concentrations in hemp compared to marijuana.

After the first seven days of treatment, 85.71 percent of the women reported an improvement. At the end of the 14 days of treatment, 100 percent of the women said they noticed an improvement.

The trial also found that 80.95 percent of the participants specifically noticed an improvement in skin texture. Also, 80.95 percent of the women reportedly noticed an improvement in the appearance of fine lines and wrinkles around the mouth.

Previous research has shown cannabinoids like CBD to have therapeutic value in the treatment of skin conditions like psoriasis and acne. A patent by the U.S. National Institutes of Health shows CBD to possess significant antioxidant and neuroprotective properties; however, CBD is not yet FDA approved for the treatment of any condition.

When the CBD infused into topical products is derived from industrial hemp and not marijuana, it’s legal to purchase in all 50 U.S. states. A recent report from Hemp Industries Association found that hemp CBD products accounted for $65 million of $573 million (11 percent) of total industrial hemp retail sales in the U.S. in 2015.

Medical Marijuana, Inc.’s investment company AXIM® Biotechnologies, Inc. is currently conducting a human clinical trial to examine the effects of cannabinoid-based topicals on the skin conditions psoriasis and eczema.

Psoriasis is an autoimmune disease that causes skin cells to rapidly build up on the skin’s surface, creating raised, red plaques and white scales. According to the International Federation of Psoriasis Associations (IFPA), there are about 150,000 new cases of psoriasis in the United States every year. Eczema, or atopic dermatitis, is associated with inflammation and causes the skin to become itchy, red, and dry. About 31.6 million people in the U.S. have symptoms of eczema, according to the National Eczema Association.

AXIM®’s proof of concept trial involves testing an ointment that contains another major cannabinoid found in cannabis, cannabigerol (CBG). Like CBD, CBG is non-psychoactive and found in higher concentrations in hemp than marijuana. Earlier research suggests that CBG has anti-inflammatory properties, may be useful for treating glaucoma, and can inhibit tumor growth.

“[CBG] has not been as well studied [as CBD], but it’s a very interesting molecule,” AXIM chief executive officer Dr. George Anastassov told Forbes earlier this year.

The trials are being overseen by Dr. Marcus Meinardi and conducted at The Maurits Clinic in The Hague, The Netherlands. In the study, one group will be treated with the CBG ointment, one will take a placebo, and a third will use a gum product containing CBG. The trial is meant to examine the CBG-based ointment’s anti-inflammatory properties.

Post by Jeffrey Stamberger

Jeffrey writes media content covering the latest in news, medical research, policy changes, and product education from the cannabis industry.

View More